I. Can't. Stand. To. Look. At. Him. Anymore. Per Bloomberg. . .
[More seriously, I'm busy, off the grid, today:]
. . . .TODAY ON BLOOMBERG TV. . . Fred Hassan of Warburg Pincus appears at 3:14 p.m. from the World Health Congress in Washington. . . .
We'll bet that he complains about health care reform, or FDA policy, or repatriation taxes -- all hindering innovation here in America. Sheesh. How about fleecing a pair of public pharma companies (while each is on the ropes) out of at least $450 million total, as stifling innovation?
3 comments:
But wait there's more: apparently Merck is buying Inspire Pharma at a 26% premium:
http://www.thestreet.com/_yahoo/story/11072557/1/merck-to-buy-inspire-for-430-million.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA
And guess who is selling its 28% share of Inspire to Merck---Warburg!
So, does Fast Freddie make even more off of Merck?
The answer would appear to be "Yes" -- in both cases!
Moreover, Warburg owns a controlling stake in Bausch + Lomb -- which company sells Zylet -- an antibacterial that would appear to DIRECTLY compete with Inspire's lead antibacterial eye care product.
And (drumroll!). . . Fast Fred is the Chairman of Bausch + Lomb (likely at Warburg's behest), to boot.
How many ways does this guy milk a system? -- Hard to say. Hard to say. . .
Thanks! -- this should probably be a new post -- and it will be, later tonight.
Namaste
Here's some more analysis, on your story, Anon.!
Namaste
Post a Comment